CGS 25997

Drug Profile

CGS 25997

Latest Information Update: 03 Sep 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Inflammation

Most Recent Events

  • 03 Sep 1996 Discontinued-Preclinical for Asthma in USA (PO)
  • 03 Sep 1996 Discontinued-Preclinical for Inflammation in USA (PO)
  • 29 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top